<DOC>
	<DOC>NCT00806481</DOC>
	<brief_summary>The purpose of this study is to determine whether lowering phosphate in patients with early chronic kidney disease with the phosphate binder sevelamer has beneficial effects on cardiovascular structure and function.</brief_summary>
	<brief_title>Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Chronic kidney disease patients aged 18 to 80 years Chronic kidney disease stage 3 (defined as a glomerular filtration rate of 3060 ml/min/1.73m2) Office blood pressure controlled to less than 140/90 mmHg for 12 months before entry into the study Total cholesterol less than 5.5 mmol/l Existing or previous treatment within 1 year with a phosphate binder or vitamin D analogue Uncontrolled hyperphosphataemia (serum phosphate &gt;1.8 mmol/l) Uncontrolled secondary hyperparathyroidism (PTH &gt;80 pg/ml) Diabetes mellitus Pregnancy Moderatesevere cardiac valvular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Phosphate</keyword>
</DOC>